Moderna Option Alert: Jun 18 $30 Puts at the Bid: 1000 vs 2329 OI; Earnings 11/6 Before Open [est] 

Moderna Option Alert: Jun 18 $30 Puts at the Bid: 1000 @ $7.05 vs 2329 OI; Earnings 11/6 Before Open [est] Ref=$28.7

Moderna

MODERNA INC

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Jim Cramer Photo by s_bukley on Shutterstock

Markets

Media

GRAL

MRNA

Le oscillazioni di Wall Street non accennano a diminuire. Il noto analista punta il dito contro la Casa Bianca e le sue politiche commerciali.

Jim Cramer accusa Trump: &#34;Il mercato è volatile? Solo se il presidente vuole&#34;

Earnings

News

Pre-Market Outlook

Trading Ideas

DKNG

PANW

Crescita, previsioni e possibili sorprese: quali opportunità si nascondono dietro i numeri? La guida per investire al meglio.

Venerdì in borsa: Palo Alto, Moderna e altre 3 azioni da monitorare

Large Cap

Health Care

General

CVAC

NVAX

Quali sono le aziende pronte a rispondere all&#39;emergenza e come potrebbe impattare sul mercato azionario? Ecco i dettagli.

Allarme influenza aviaria: nuovo caso in USA. Ecco 4 azioni da tenere d&#39;occhio

Moderna Inc

Events

Press Releases

Moderna to Present at Upcoming Conferences in September 2025

Biotechs Big Bang: IPOs, Uplists and the Short Squeeze Effect

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1

Legal

Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism

Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans

Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories

Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans

Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK

FHTX

PPCB

RHHVF

SANA

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Leerink Partners

Barclays

B of A Securities

JP Morgan

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-03-13 at 5.45.52 PM

Biotech

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Comments

Moderna

Unusual Options Activity for

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO